Placebo-liraglutide

University of Aarhus · FDA-approved active Small molecule

Placebo-liraglutide is a Small molecule drug developed by University of Aarhus. It is currently FDA-approved. Also known as: Isotonic saline.

This is a placebo control formulation used in clinical trials to compare against liraglutide's active GLP-1 receptor agonist effects.

At a glance

Generic name	Placebo-liraglutide
Also known as	Isotonic saline
Sponsor	University of Aarhus
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

Placebo-liraglutide refers to an inert comparator arm in clinical studies of liraglutide, the active GLP-1 receptor agonist. It contains no pharmacologically active ingredient and serves as a control to isolate the true therapeutic effects of liraglutide from placebo response. This is a research tool rather than a therapeutic agent.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Effects of GH and Lirglutide on AgRP (PHASE4)
• SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (PHASE3)
• A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis (PHASE2)
• The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes (PHASE2)
• Liraglutide Effects on Epicardial Fat Inflammatory Genes (PHASE4)
• Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee (PHASE1)
• Saxenda: Underlying Mechanisms and Clinical Outcomes (PHASE4)
• Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo-liraglutide CI brief — competitive landscape report
• Placebo-liraglutide updates RSS · CI watch RSS
• University of Aarhus portfolio CI

Frequently asked questions about Placebo-liraglutide

What is Placebo-liraglutide?

Placebo-liraglutide is a Small molecule drug developed by University of Aarhus.

How does Placebo-liraglutide work?

This is a placebo control formulation used in clinical trials to compare against liraglutide's active GLP-1 receptor agonist effects.

Who makes Placebo-liraglutide?

Placebo-liraglutide is developed and marketed by University of Aarhus (see full University of Aarhus pipeline at /company/university-of-aarhus).

Is Placebo-liraglutide also known as anything else?

Placebo-liraglutide is also known as Isotonic saline.

What development phase is Placebo-liraglutide in?

Placebo-liraglutide is FDA-approved (marketed).

Related

• Manufacturer: University of Aarhus — full pipeline
• Also known as: Isotonic saline